Baxdrostat meets primary and all secondary endpoints in BaxHTN phase III trial in patients with uncontrolled or treatment resistant hypertension: Cambridge, UK Wednesday, July 16, ...

AZN hits all endpoints in phase III study for baxdrostat, a first-in-class treatment targeting hard-to-manage hypertension.

SAN FRANCISCO -- The investigational selective glucocorticoid receptor modulator relacorilant led to improvements in blood ...

CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today that the Centers for Medicare ...

The offering, the first IPO this year, attracted more than 32 billion dirhams ($3.5 bln) in demand for 500 million dirhams in shares. GSK seeks FDA nod for expanded use of RSV vaccine in adults ...

Dont wait for symptoms to show up! Learn how regular doctor visits can help detect health issues early and prevent serious ...

‘A higher-than-expected cardio age can predict higher risk of stroke and heart attack, reduced exercise capacity, cognitive decline and reduced lifespan,’ she adds. ‘The upside is it's often ...

Health ministry issues directive for public venues to carry cautionary notices aimed at making people 'aware about hidden ...

The 24-year study of more than 1.2 million children in Denmark found that aluminum exposure didn't raise the risk of autism, asthma, or other chronic diseases. Other science and research news is on ...

The Mumbai man was told by the hospital that bariatric surgery, when combined with lifestyle changes, can be a life-saving solution for many ...